Developed by Pfizer Global Research and Development, capravirine is a Non-Nuclesoide Reverse Transcriptase Inhibitor (NNRTI) that was under development for the treatment of patients infected with the Human Immunodeficiency Virus (HIV). It was indicated for patients with HIV/AIDS who had failed on currently available antiretroviral therapies.

Dr. Fortuna says payers should consider expand their perspectives on improving the healthcare system by adopting the use of the tools, methodologies and quality improvement professionals (engineers) that other industries have with great success as recommended in the May report of the President’s Council of Advisors on Science and Technology (PCAST). Incenting providers to do the same would also assist in the effort to remove waste and improve operations, culture and clinical care.

More Articles ...

Sign up via our free email subscription service to receive notifications when new information is available.